VANCOUVER, BC, March 30,
2023 /PRNewswire/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF),
a mental health care company advancing innovative treatments and
safe, evidence-based psychedelic-assisted therapies, will release
its financial results for the quarter ended February 28, 2023, after market close on
Thursday, April 13, 2023.
Interested parties are invited to participate in the Company's
Q2 2023 results conference call and webcast occurring on the same
day, at 5:30 p.m. Eastern time /
2:30 p.m. Pacific time. During the
call, Numinus executives will review the Company's performance and
recent initiatives, and answer questions from analysts.
To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/711589893
The webcast will also be archived on the Events and
Presentations page of Numinus' Investor Relations website:
https://www.investors.numinus.com/events-and-presentations
To participate in the live conference call, please use the
following dial-in information:
- 1 (888) 330-3632 (Toll-free North
America)
- 1 (646) 960-0837 (International)
- Please ask to participate in Numinus' Q2 2023 Results
Call.
To avoid any delays in joining the call, please dial in at least
five minutes prior to the call start time. If prompted, please
provide conference passcode 3547386.
A replay of the conference call can also be accessed after
8:30 p.m. Eastern time / 5:30 p.m. Pacific time on April 13, 2023, at 1-800-770-2030 or
1-647-362-9199 (using passcode 3547386). The replay will be
available until April 27, 2023.
About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well
through the development and delivery of innovative mental health
care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model - including psychedelic production,
research and clinic care - is at the forefront of a transformation
aimed at healing rather than managing symptoms for depression,
anxiety, trauma, pain and substance use. At Numinus, we are leading
the integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking
statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements. Forward-looking statements are based on
estimates and opinions of management at the date the statements are
made. There is no assurance that Health Canada will approve the
application. The Company does not undertake any obligation to
update forward-looking statements even if circumstances or
management's estimates or opinions should change except as required
by applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/numinus-to-host-q2-2023-results-conference-call-on-april-13-2023-301785686.html
SOURCE Numinus Wellness Inc.
